Recent news releases
-
Jun 30, 2026 Apotex first to receive Health Canada approval for SEVMIA™, a generic semaglutide for chronic weight management
-
Jun 16, 2026 Apotex Health Corp. announces closing of upsized initial public offering and exercise of over-allotment option in full
-
Jun 10, 2026 Apotex Health Corp. files final prospectus and announces pricing of upsized initial public offering
-
Jun 9, 2026 Apotex Health Corp. upsizes its initial public offering
-
Jun 3, 2026 Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
-
Jun 1, 2026 Apotex Health Corp. launches its initial public offering
-
May 28, 2026 Apotex Health Corp. files preliminary prospectus for initial public offering
-
May 26, 2026 Apotex expands ophthalmic portfolio with Health Canada approval of IHEEZO™
-
May 14, 2026 Apotex launches Apo-Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada
-
May 1, 2026 Apotex becomes the first Canadian-based global pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic®